COMPASS Pathways plc (NASDAQ: CMPS) - Deep Dive Research Report

Prepared 2026-07-11. All figures operational, not valuation. No price targets, no recommendation.

Section 1: What the Company Does

COMPASS Pathways is a clinical-stage biotechnology company trying to turn a psychedelic - synthetic psilocybin, the active compound in "magic mushrooms" - into an approved prescription medicine for depression that has failed every other drug. It has no product on the market, no revenue from products, and no customers in the ordinary sense. What it has is a single lead drug candidate called COMP360, a proprietary, patented, synthesised crystalline formulation of psilocybin, which it is pushing through the final stages of US regulatory approval for treatment-resistant depression (TRD) - depression in patients who have not responded to at least two prior antidepressants.

The core idea is unusual and worth stating plainly. COMP360 is not a pill a patient takes home. It is a supervised, in-clinic experience. A patient with severe, treatment-resistant depression is given a single 25mg oral dose of psilocybin in a calm, controlled room, wearing eyeshades and headphones, with a specially trained therapist present for the entire six-to-eight-hour session. The patient does not go back on a daily drug. The therapeutic bet is that one or two of these sessions can produce a rapid and durable reduction in depression that lasts weeks or months - something no daily antidepressant delivers. In the company's own framing, it offers what no approved TRD drug does: clinically meaningful efficacy with both rapid onset and extended durability.

The company was founded in London in 2016 by George Goldsmith, his wife Dr. Ekaterina Malievskaia, and Lars Christian Wilde. The founding is personal, not opportunistic: Goldsmith and Malievskaia started COMPASS after their own son suffered a severe mental-health crisis and they collided with the limits of conventional psychiatric care. That origin still shapes the company's positioning as a patient-first mental-health company rather than a recreational-drug play. Early backing came from a distinctive investor set - Peter Thiel (Thiel Capital), Christian Angermayer (Apeiron Investment Group, and separately the founder of atai Life Sciences, now a competitor), and Japanese pharma Otsuka. COMPASS listed on Nasdaq in September 2020.

The hard part of this business is not chemistry - psilocybin is a known molecule. The hard part is threefold. First, running the trials: psychedelic trials are extraordinarily difficult to blind (patients and clinicians can usually tell who got the active dose), which makes clean, regulator-grade efficacy data hard to produce. COMPASS ran the largest and most rigorous psilocybin trials ever attempted to solve this. Second, the regulatory and legal overhang: psilocybin is a US Schedule I controlled substance, meaning the government currently classifies it as having no accepted medical use. FDA approval is not enough - the drug must also be rescheduled by the DEA before a single prescription can be written. Third, building an entirely new delivery model: an approved COMP360 is useless without a network of certified sites and trained therapists to administer it, so COMPASS is simultaneously trying to invent the commercial infrastructure for a category that does not yet exist.

"COMP360 has therefore demonstrated what no approved drug for TRD offers, clinically meaningful efficacy with both rapid onset and extended durability." - Kabir Nath, CEO, Q1 2026 earnings call (May 13, 2026)

A concrete walk-through of what the product actually is: a 45-year-old patient who has cycled through four antidepressants with no relief is referred to a certified COMP360 treatment centre. Over preparatory sessions, a trained therapist builds rapport and sets expectations. On dosing day, the patient swallows a 25mg capsule, settles onto a couch with eyeshades and a curated music playlist, and the therapist sits with them for the six-to-eight-hour psychedelic experience, intervening only for reassurance or safety. In the following days, "integration" sessions help the patient process the experience. The clinical trials suggest that for a meaningful minority of patients, this single experience meaningfully lifts depression for months. That is the entire value proposition - and the entire business.

Section 2: Business Segments

COMPASS Pathways is a single-asset, single-therapeutic-area clinical-stage company. It has no reportable operating segments, no divisions, and no product revenue to allocate. Effectively 100% of its activity is the development of one molecule, COMP360 psilocybin, across a small number of psychiatric indications.

Because "segments" do not exist in the conventional sense, the useful way to understand the company is by development programme, which is how management itself organises the story:

1. COMP360 in Treatment-Resistant Depression (TRD) - the entire company. This is the lead programme and the reason the company exists. It is in Phase 3, the final clinical stage, running two pivotal trials (COMP005 and COMP006). This programme carries essentially all of the company's near-term value and is the basis for the New Drug Application (NDA) now being submitted to the FDA. Everything else is optionality.

2. COMP360 in Post-Traumatic Stress Disorder (PTSD) - the pipeline extension. A second indication for the same molecule. A Phase 2 open-label study in 22 participants showed COMP360 was generally safe and well-tolerated with durable symptom improvement out to 12 weeks after a single dose. The FDA accepted the IND (Investigational New Drug) application, and a Phase 2b/3 trial was initiated in 2026. PTSD matters because it lets COMPASS reuse the same drug, the same delivery model, and the same commercial infrastructure to open a second large market with limited incremental cost - it is a strategic option, not a current value driver.

There is no cash-cow segment, no margin engine, no diversification. This is a binary, one-drug company where the TRD programme is the whole thesis and PTSD is a call option layered on top of it. That concentration is the single most important fact about the business and colours every other section of this report.

Section 3: Products and Business Detail

The product: COMP360. COMP360 is COMPASS's proprietary, synthetic, crystalline polymorph formulation of psilocybin. The distinction between "psilocybin" and "COMP360" is the entire intellectual-property story. Psilocybin as a molecule cannot be patented - it occurs in nature. What COMPASS did was develop a specific, reproducible, high-purity crystalline form of synthetic psilocybin (a particular polymorph, "Polymorph A") together with a manufacturing process to produce it consistently at scale and pharmaceutical purity. That crystalline form and process are patented, and they are what stops a generic manufacturer from simply copying the drug the day it is approved. This is the classic small-molecule-formulation moat: the compound is old, the specific manufacturable form is proprietary.

The delivery model is part of the product. COMP360 is inseparable from the psychological-support protocol around it. An approved COMP360 will almost certainly carry a REMS (Risk Evaluation and Mitigation Strategy) requiring administration only at certified sites by trained facilitators. This means the "product" COMPASS sells is really a drug-plus-service system: the capsule, the certification programme for sites and therapists, the training curriculum, the session protocol, and the digital tools that support it. COMPASS has spent years building the training and certification apparatus precisely because the drug alone cannot be commercialised.

The clinical evidence base (the real "product spec" for a pre-approval biotech):

• COMP005 (first pivotal Phase 3): 258 patients, single 25mg dose vs placebo. Met its primary endpoint - a 3.6-point greater reduction on the MADRS depression scale vs placebo at week 6, highly statistically significant. Roughly 25% of patients achieved a clinically meaningful response to a single dose. Investors reacted with disappointment to the 3.6-point spread, viewing it as modest, even though it was statistically clean.

• COMP006 (second pivotal Phase 3): 581 dosed participants across North America and Europe, a three-arm design testing two doses given three weeks apart at 25mg vs 10mg vs 1mg (active comparator design). In the 25mg arm, ~39% of participants achieved a clinically meaningful response by week 6, and that response was durable at least through week 26 (six months). Notably, nearly 30% of week-6 responders went into remission after the second dose (retreatment) in Part B. This July 7, 2026 readout was materially stronger than COMP005 and directly addressed the "is the effect big and durable enough?" critique.

Together the programme has enrolled over 1,000 patients - the largest psilocybin clinical dataset ever assembled. The two trials are structured in parts: Part A (blinded through 6 weeks), Part B (blinded through 26 weeks), Part C (open-label extension to 52 weeks).

Manufacturing. COMP360 is manufactured synthetically (not extracted from mushrooms) through contract manufacturing, giving batch-to-batch consistency and pharmaceutical-grade purity - a requirement for FDA approval that wild or cultivated psilocybin cannot meet. The synthetic route and crystalline form are the manufacturing IP.

Geography. The company is UK-headquartered (London) but the commercial prize is the United States, where the TRD market is largest, the regulatory pathway is furthest advanced, and reimbursement infrastructure (via the existing Spravato model) already exists. Trials ran across North America and Europe. Initial commercialisation is US-first.

Milestones that changed the business: FDA Breakthrough Therapy designation for TRD (2018); Nasdaq IPO (2020); COMP005 primary-endpoint success (June 2025); COMP006 primary-endpoint success and six-month durability (announced through 2026, with the definitive 26-week Part B data on July 7, 2026); FDA granting a rolling NDA submission and awarding a Commissioner's National Priority Voucher (CNPV) in 2026, which could compress the review window to as little as 1-2 months after final submission.

Section 4: Customers

COMPASS has no product customers yet - it is pre-approval and pre-revenue. But its commercial strategy defines exactly who the customers will be, and that plan is unusually concrete for a pre-launch biotech.

Who will buy. The buyers are not patients directly. They are the interventional psychiatry treatment centres - specialised clinics that already administer in-office interventional treatments for depression, principally Spravato (esketamine, Johnson & Johnson's nasal-spray ketamine derivative) and TMS (transcranial magnetic stimulation). COMPASS's commercial team has explicitly targeted the roughly 7,500 interventional psychiatric treatment centres already prescribing Spravato as its beachhead. These sites already have the physical rooms, monitoring staff, payer relationships, and clinical comfort with supervised in-office psychiatric treatment - exactly the infrastructure COMP360 needs.

Who inside the customer decides. The prescribing psychiatrist and the clinic's medical director make the adoption decision; the clinic's operations and billing staff decide whether the economics work. The criteria are: does the drug have clean efficacy and safety data, is it reimbursed by payers, and does administering it fit the clinic's existing chair-time and staffing model. The Spravato analogue is doing a lot of work here - if a site already runs supervised esketamine sessions, adding supervised psilocybin sessions is an incremental, not transformational, change.

Why they will choose COMP360. The pitch is differentiation on durability and dosing burden. Spravato requires repeat dosing (twice weekly tapering to biweekly) more or less indefinitely; COMP360's trials point to durable benefit from one or two sessions. A clinic can offer patients a fundamentally different value proposition - "a couple of sessions, not an indefinite regimen." Management has repeatedly leaned on the Spravato reference point, noting Spravato is expected to reach ~$3 billion in revenue by 2027 while treating less than 2% of the roughly 4 million US TRD patients, i.e. the category is validated but barely penetrated.

Switching costs and lock-in. The lock-in cuts in COMPASS's favour once sites are certified. Under a likely REMS, only certified sites with trained therapists can administer COMP360. That certification is a barrier for the clinic to start, but once done it creates a trained, credentialed installed base that is sticky. It also raises a barrier for any later psilocybin competitor, who would need to re-certify the same sites.

Concentration and contract structure. There is no revenue concentration to assess yet. Post-launch, revenue predictability will hinge on payer reimbursement decisions and the pace of site certification, not on a few large contracts. The state-rescheduling dynamic is a key access variable management flagged: nearly 90% of the US population lives in a state that intends to reschedule COMP360 within 30 days of FDA approval and DEA rescheduling, which would sharply accelerate the speed at which certified sites can begin treating patients.

Section 5: Competitive Landscape

The competitive question for COMPASS has two layers: competition within psychedelics (who else is trying to build a supervised-psychedelic depression drug) and competition from the incumbent standard of care in treatment-resistant depression (what a psychiatrist would use today).

The incumbent to beat: Spravato (esketamine). Johnson & Johnson's Spravato is the reference product and the real competitor. It is FDA-approved for TRD (and now as a monotherapy), it is reimbursed, it is administered in-office under supervision, and it has built exactly the interventional-clinic channel COMPASS wants to sell into. Spravato is both COMPASS's competitor and its proof of concept - it demonstrates that payers and clinics will support a supervised, in-office depression treatment. COMP360's differentiation claim is durability (one or two sessions vs an ongoing esketamine regimen).

The direct psychedelic competitors are chasing the same TRD market with different molecules and, crucially, shorter psychedelic sessions, which is a real competitive axis because a shorter experience means less clinician chair-time per patient and better clinic economics:

• atai Life Sciences / Beckley Psytech (merged into "AtaiBeckley") - developing BPL-003 (intranasal 5-MeO-DMT/mebufotenin), a fast-acting, short-duration psychedelic (a session measured in ~90 minutes rather than 6-8 hours). Beckley's Phase 2b hit its endpoints, moving it toward late-stage trials. This is the most direct strategic threat because a shorter session attacks COMPASS's biggest practical weakness - clinic throughput. Notably, atai's founder Christian Angermayer was also an early COMPASS backer, so the rivalry has tangled roots.
• GH Research - developing GH001 (inhaled mebufotenin/5-MeO-DMT) for TRD, also a very short-duration psychedelic experience with rapid onset.

Competitor comparison:

Market-cap figures are approximate peer-size references only, move constantly, and should be re-checked; they are not applied to COMPASS.

Where COMPASS wins. It has the largest, most rigorous, most advanced clinical dataset in the field (over 1,000 patients, two positive Phase 3 trials), a genuine head start toward being the first FDA-approved psilocybin medicine, a patented crystalline formulation, Breakthrough Therapy designation, and the regulatory momentum of a rolling NDA plus the National Priority Voucher. First-mover certification of the interventional-clinic base is a real, if not permanent, advantage.

Where COMPASS is exposed. The 6-8 hour session length is its structural weakness - competitors offering a 90-minute experience can treat far more patients per clinic-day, which matters enormously to clinic economics and payer cost calculations. The COMP005 efficacy spread (3.6 MADRS points) was underwhelming enough that critics question whether the effect is large enough to command premium pricing and enthusiastic prescribing, though the stronger, durable COMP006 second-dose data pushes back on that.

Barriers to entry. They are moderate-to-high but not absolute. High: the cost and difficulty of running blinded psychedelic Phase 3 trials, the crystalline-form patents, Schedule I regulatory friction, and the need to build a certified-site network. Not absolute: the underlying molecules are un-patentable, several well-funded competitors are already in late-stage trials, and a shorter-duration competitor could leapfrog on the dimension clinics care about most.

Section 6: Industry

The demand driver is unmet need in depression. Depression is one of the largest disease burdens globally, and treatment-resistant depression - patients who fail two or more antidepressants - is a large, poorly-served subset. Management sizes the US TRD population at roughly 4 million patients. The demand for a genuinely differentiated TRD treatment is not in question; the standard-of-care SSRIs and SNRIs leave a large fraction of patients unwell, and the only novel supervised option, Spravato, treated less than 2% of TRD patients as of 2025 despite heading toward ~$3 billion in revenue by 2027. That gap - a validated category with tiny penetration - is the entire industry opportunity.

Industry size and trajectory. The interventional-psychiatry channel is real and growing: the ~7,500 Spravato-prescribing centres and expanding TMS and ketamine-clinic footprint represent an infrastructure that did not exist a decade ago. The broader "psychedelic medicine" industry is nascent - no psychedelic is yet FDA-approved for depression - so the market is pre-formation, with its size entirely contingent on the first approvals. If COMP360 is approved, it would help create the category rather than take share in an existing one.

Where COMPASS sits in the value chain. COMPASS is the drug developer and, uniquely, the builder of the delivery protocol and certification layer. It sits upstream (manufacturing the synthetic drug substance via contract manufacturers) and reaches toward the point of care by defining how sites and therapists must be trained and certified. It does not own clinics; it enables and certifies third-party interventional-psychiatry sites.

Regulation is the dominant industry force. Two gates matter. First, FDA approval based on the pivotal trials - now in progress via a rolling NDA, with the Commissioner's National Priority Voucher potentially compressing review to 1-2 months after final submission. Second, and unique to this category, DEA rescheduling: psilocybin is Schedule I, and even after FDA approval it must be moved to a less restrictive schedule before it can be prescribed. On top of the federal picture sits a patchwork of state-level rescheduling, where management says nearly 90% of the US population lives in states intending to reschedule within 30 days of federal approval. Reimbursement policy (whether payers cover the drug plus the clinician time) is the third regulatory-adjacent variable that will shape the market's real size.

Cyclicality. The underlying disease demand is non-cyclical - depression does not track GDP. But the company itself is acutely sensitive to the biotech funding cycle: as a pre-revenue, cash-burning company, its ability to fund operations depends on capital-market access, which is highly cyclical. When biotech sentiment sours, financing gets expensive and dilutive.

Tailwinds: de-stigmatisation of psychedelic medicine, the FDA's demonstrated willingness to grant Breakthrough and priority pathways, state-level rescheduling momentum, and the proof-of-concept that Spravato provides for supervised in-office depression treatment. Headwinds: the unresolved federal Schedule I status, uncertain payer economics for a labour-intensive supervised therapy, and a crowded late-stage psychedelic pipeline racing toward the same indication with shorter, cheaper-to-administer sessions.

Section 7: Growth Triggers

All triggers below are drawn from the six most recent earnings calls and dated company disclosures.

• Final NDA submission on track for Q4 2026, launch-ready by end of 2026. Management has repeatedly stated the goal of being commercially launch-ready by year-end 2026. (Repeated across Q3 2025, Q4/FY2025, and Q1 2026 calls; Q1 2026 call, May 13, 2026)

  "We remain focused on being launch ready by the end of the year." - Lori Englebert, CCO, Q1 2026 call (May 13, 2026)

• COMP006 26-week Part B data - the final NDA data set - delivered positive. Guided as the last module needed to complete the rolling NDA; the six-month durable data was released July 7, 2026, showing ~39% response in the 25mg arm sustained through week 26. (Guided Q3 2025 call, Nov 4, 2025 and Q1 2026 call, May 13, 2026; delivered July 7, 2026)

  "Part B data from 006 ... will be the final data set to complete the submission." - Kabir Nath, CEO, Q1 2026 call (May 13, 2026)

• FDA rolling NDA review already underway plus Commissioner's National Priority Voucher. The rolling submission lets COMPASS file modules as data matures, and the CNPV carries the potential for an "ultra-accelerated" 1-2 month review after final submission. (Q4/FY2025 call, March 24, 2026 and Q1 2026 call, May 13, 2026)

  "One benefit ... includes the potential for an ultra accelerated review time line of 1 to 2 months after final NDA submission." - Lori Englebert, CCO, Q1 2026 call (May 13, 2026)

• Commercial build-out accelerated 9-12 months; sales team scaling. Management pulled forward launch-readiness plans by roughly a year and has been doubling the commercial team; the go-to-market targets the ~7,500 interventional psychiatry centres already prescribing Spravato. (Q3 2025 call, Nov 4, 2025; team-doubling detail Q1 2026 call, May 13, 2026)

• State-level rescheduling to speed patient access. Nearly 90% of the US population lives in states that intend to reschedule COMP360 within 30 days of FDA approval and DEA rescheduling. (Q1 2026 call, May 13, 2026)

• PTSD Phase 2b/3 program initiating - second indication. Following FDA acceptance of the IND, COMPASS is starting a late-stage PTSD trial, extending the same molecule and delivery model to a second large market. (Q4/FY2025 call, March 24, 2026)

• Cash runway extended well beyond launch into 2028. A February 2026 $150M financing plus ~$200M of warrant exercises pushed the runway past the anticipated launch, removing near-term financing pressure through the approval window. (Q4/FY2025 call, March 24, 2026 and Q1 2026 call, May 13, 2026)

Section 8: Key Risks

Regulatory rejection or delay at the FDA. The mechanism is direct: the entire company value rests on approval of one drug in one indication. If the FDA judges the efficacy insufficient (the COMP005 3.6-point MADRS spread was viewed by some as modest), demands additional trials, or raises safety/functional-unblinding concerns about psychedelic trial design, the timeline resets by years and the cash runway assumptions collapse. This is a high-impact risk; the probability is meaningfully reduced by two positive Phase 3 trials and the rolling review, but not eliminated - the FDA has not yet approved any psilocybin medicine.

DEA rescheduling is a separate, non-FDA gate. Even a clean FDA approval does not let anyone write a prescription. Psilocybin must be moved off Schedule I by the DEA, a process outside COMPASS's control and on its own timeline. A slow or contested rescheduling would delay revenue even after approval. Management's state-rescheduling data is encouraging but is contingent on the federal action happening first.

The trials produced statistically valid but clinically debated efficacy. COMP005's 3.6-point difference disappointed investors ("investors unimpressed," per contemporaneous coverage). The mechanism of harm is commercial, not regulatory: a drug that clears the statistical bar but underwhelms clinicians may see slow uptake, weak pricing power, and lukewarm payer support. The stronger, durable COMP006 second-dose data partly answers this, but the durability-vs-effect-size debate remains live.

Competition on session length. COMPASS's 6-8 hour supervised session is expensive in clinician chair-time. Competitors (AtaiBeckley's BPL-003, GH Research's GH001) offer ~90-minute experiences. If a shorter-duration psychedelic reaches approval with comparable efficacy, clinics may prefer it on pure throughput economics, eroding COMPASS's first-mover certification advantage. This is a moderate-probability, high-impact structural risk.

Financing and dilution. As a pre-revenue company burning $120-145M/year (2025 guidance), COMPASS survives on capital markets. Although management secured runway into 2028, any launch delay, additional trial requirement, or biotech-funding downturn forces further raises. The 2026 financings and warrant exercises already added shares; a binary-outcome biotech that needs to raise into weakness dilutes heavily.

Reimbursement and delivery-model friction. Even approved and rescheduled, COMP360 requires certified sites, trained therapists, and payers willing to reimburse both drug and hours of supervised clinician time. If payers balk at the labour cost, real-world uptake could lag the addressable-population math badly - the same reason Spravato reaches under 2% of TRD patients despite years on the market.

Single-asset, binary company. The overarching risk is concentration: one drug, one lead indication, no revenue diversification. Any single adverse event - a regulatory setback, a safety signal, a failed confirmatory analysis - has no offset elsewhere in the business.

Section 9: Walk the Talk

The six calls used for this assessment: Q4/FY2024 (Feb 27, 2025), Q1 2025 (May 8, 2025), Q2 2025 (July 31, 2025), Q3 2025 (Nov 4, 2025), Q4/FY2025 (March 24, 2026), and Q1 2026 (May 13, 2026). The most recent is within 60 days of today.

The dominant pattern across these calls is a management team that has been specific with clinical and regulatory timelines and has largely hit them - the rare thing for a psychedelic biotech, a field littered with slipped readouts.

Start at the beginning. On the Q4/FY2024 call (Feb 27, 2025), management guided that COMP005 six-week topline data would arrive in Q2 2025 and that COMP006 26-week data would come in the second half of 2026. On the Q1 2025 call (May 8, 2025), CEO Kabir Nath sharpened the near-term promise:

"[We] eagerly await the upcoming topline 6-week data readout, on track for late June, the first data from our pivotal phase 3 COMP360 program in treatment resistant depression." - Kabir Nath, Q1 2025 call (May 8, 2025)

That readout landed on schedule: COMP005 hit its primary endpoint in June 2025, and the result was formally reported on the Q2 2025 call (July 31, 2025). Promise made in February and May, delivered in June - a clean hit on the single most-watched catalyst. The honest wrinkle is that while the timeline was met, the magnitude (3.6 MADRS points) disappointed the market; management delivered the data they promised on the date they promised, but the data itself was more modest than bulls hoped.

The next commitment concerned acceleration. On the Q3 2025 call (Nov 4, 2025), management announced it was pulling the commercial launch forward by 9-12 months and moving to a potential rolling NDA submission after a positive FDA meeting. This was an upgrade to prior guidance, not a walk-back. It was then substantiated: by the Q4/FY2025 call (March 24, 2026) the FDA had granted the rolling review and awarded the Commissioner's National Priority Voucher, and by the Q1 2026 call (May 13, 2026) the rolling NDA was actively underway with modules being submitted. The "we will be launch-ready by end of 2026" promise has been repeated consistently across three straight calls without slipping - a good sign of message discipline.

The final and most important trackable promise: management repeatedly guided that COMP006 26-week Part B data would be the last data set to complete the NDA, expected in early Q3 2026. That data was delivered on July 7, 2026 - squarely on schedule - and it was positive and durable, arguably stronger than COMP005. Guidance set on the Q3 2025 and Q1 2026 calls, delivered on time.

On the timeline where they had less control - COMP005's efficacy magnitude - management was optimistic in tone but did not over-promise a specific effect size, so there is no broken numeric promise to point to. The one area to watch is the launch-readiness claim: "launch-ready by end of 2026" is repeated confidently, but it depends on FDA approval and DEA rescheduling that are outside management's control, so the promise is only as good as those external gates.

Assessment: this is management that does what it says on clinical and regulatory timing. Across six calls, every dated clinical readout arrived on or close to schedule, and every regulatory milestone they guided toward materialised. The credibility gap is not in execution but in the two things they cannot fully control - the ultimate FDA decision and DEA rescheduling - and in the fact that hitting a timeline does not guarantee the market loves the underlying data (COMP005 proved that). They are consistent and accurate, not obviously promotional.

Section 10: Shareholder Friendliness Index

Dividends. COMPASS Pathways has never paid a dividend and pays no dividend today. DPS for each of the last three financial years (2023, 2024, 2025) was $0.00. This is entirely expected and appropriate: the company is a pre-revenue, loss-making clinical-stage biotech (FY2024 net loss of $155.1 million, or $2.30 per share) that needs every dollar of capital to fund trials and prepare for launch. There is no payout ratio to discuss because there are no earnings.

Buybacks and dilution. There has been no share buyback program authorised or executed over the last three years, and none would be expected - a cash-burning biotech retiring shares would be self-defeating. The share count has moved decisively in the opposite direction: the company has repeatedly issued equity to fund itself. In January 2025 it raised $150 million gross, in February 2026 it raised a further $150 million, and it saw roughly $200 million of warrants exercised in early 2026 (a warrant exercise gain of ~$91.2 million ran through Q1 2026). Each of these adds shares. The direction over three years is unambiguously growing share count from capital raises, warrant exercises, and routine option/RSU issuance - shareholders have been diluted, and will likely be diluted further if launch requires additional capital. Insider equity activity over the period is consistent with this: option grants to directors and executives and tax-withholding share dispositions on RSU vesting, not open-market returns of capital.

(Sources: FY2024 results, Feb 27, 2025; FY2025 results, March 24, 2026; Q1 2026 results, May 13, 2026.)

Verdict: Hoards Capital (by necessity, not choice) - a pre-revenue biotech that pays no dividend, runs no buyback, and dilutes shareholders through serial financings to fund its single drug toward approval; capital return is simply not the stage this company is at.

Section 11: Insider Activities

Insider transactions for CMPS are filed on SEC Form 4 via EDGAR. Over the last twelve months, the filings show routine compensation-related activity and no open-market purchases or open-market sales by insiders. The pattern is grants and tax-withholding, not conviction trading.

Buys - read the signal. There were no open-market insider purchases in the last twelve months. That is not itself a red flag for a pre-revenue biotech - insiders here are compensated in options and RSUs rather than buying stock, and open-market buying is rare in the sector - but it does mean there is no bullish insider-buying signal to point to. Worth noting for context: the director option grants carry an $11.85 strike, well above the ~$6.61 level at which the CEO's February 2026 tax withholding was priced, implying the share price appreciated materially between early 2026 and the later grants (consistent with the positive Phase 3 news flow). That is a market signal, not an insider-conviction signal.

Sells - work out the why. There were no discretionary open-market sales. The only dispositions were shares automatically withheld by the company to cover taxes on vesting RSUs (Kabir Nath, Teri Loxam) - the most benign category of insider "sale," mechanical and unrelated to any view on the business. These should not be read as insiders reducing exposure.

Net assessment. Insiders are neither meaningful net buyers nor discretionary net sellers - the twelve months of activity is entirely compensation-driven (option grants in, tax-withholding shares out). There is no open-market conviction signal in either direction. For a binary clinical-stage company this is normal and the correct read is neutral: the absence of insider selling into the positive Phase 3 news flow is mildly reassuring, but the absence of any open-market buying means insiders have not put fresh personal capital behind the stock either.

Section 12: Scenarios

Bull case. The COMP006 six-month durability data proves to be the turning point in the efficacy debate. The FDA, working through the rolling NDA and leaning on the National Priority Voucher, approves COMP360 for treatment-resistant depression faster than the market expects - potentially within a compressed post-submission window. DEA rescheduling follows, and because nearly 90% of the US population lives in states poised to reschedule within thirty days, patient access opens quickly and broadly. The commercial team, doubled and drawn from people who have collectively launched dozens of products, plugs COMP360 into the existing 7,500 interventional-psychiatry clinics already running Spravato, and the "one or two sessions, durable relief" pitch resonates with psychiatrists frustrated by esketamine's indefinite regimen. Payers, seeing durability, reimburse. COMP360 becomes the first approved psilocybin medicine, defines the category, and the PTSD Phase 2b/3 delivers, turning a single-indication story into a platform. COMPASS goes from cash-burning developer to the anchor of a new therapeutic class.

Base case. COMPASS completes the NDA on schedule and the FDA, after review, approves COMP360 for TRD - but the path is a bit slower and messier than the bull case. Rescheduling and payer negotiations take time, and initial uptake is gradual as clinics work through the economics of six-to-eight-hour supervised sessions and the certification process. The drug launches into a real but modest early ramp, treating a growing but small slice of the four-million-patient TRD population, much as Spravato did in its early years. Competition from shorter-session psychedelics looms but has not yet reached the market. The company draws on its runway into 2028, likely raises additional capital to fund the commercial build and the PTSD program, and settles in as a genuine commercial-stage company whose ultimate scale depends on how quickly the delivery model and reimbursement mature. Management continues to hit its timelines, as it has across the last six calls.

Bear case. The efficacy debate that started with COMP005's 3.6-point MADRS spread never fully resolves. The FDA, unconvinced the benefit is large enough relative to the burden of a supervised psychedelic session, requests additional data or narrows the label - and even in a clean approval, DEA rescheduling drags, delaying any prescriptions. When COMP360 does reach clinics, payers balk at reimbursing hours of clinician chair-time for a treatment whose real-world durability is uneven, and uptake stalls the way Spravato's did, but without J&J's balance sheet behind it. Meanwhile AtaiBeckley's BPL-003 or GH Research's GH001 reach approval with comparable efficacy in a 90-minute session, and clinics choose the option with better throughput economics. Forced to keep funding a slow launch and a second PTSD program, COMPASS raises capital repeatedly into a weak biotech tape, diluting shareholders heavily. The single-asset concentration that was the whole thesis becomes the whole problem.